Allergan Press Releases

DUBLIN, May 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced it will showcase data during the upcoming American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18 – May 22, 2019. Data being presented include research on VRAYLAR^® (cariprazine) that investigates its use for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients.

DUBLIN, May 9, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that Chief Financial Officer Matthew Walsh will participate in a fireside chat at the Bank of America Merrill Lynch 2019 Health Care Conference in Las Vegas, Nevada. The presentation will begin at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time) on Tuesday, May 14, 2019.

DUBLIN, May 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today reported its first quarter 2019 financial results including GAAP net revenues of $3.60 billion, a 2.0 percent decrease from the prior year quarter. FIRST QUARTER 2019 FINANCIAL RESULTS Executive Commentary "Our first quarter results reflected continued growth of our Core Business, which increased 4.4 percent year-over-year across our four key therapeutic areas. Growth of key products such as BOTOX^® Cosmetic, BOTOX^® Therapeutic, VRAYLAR^®, JUVÉDERM^® and Lo LOESTRIN^® offset declines in products that lost exclusivity and products which were divested in 2018," said Brent Saunders, Chairman and CEO of Allergan. "Many key R&D programs have made steady progress and we now anticipate five regulatory approvals over the next 18 months. I appreciate the talented Allergan colleagues around the world who are bringing our products to patients who need them and positioning Allergan for a successful 2019 and beyond."

DUBLIN, May 3, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2019. The dividend will be paid on June 14, 2019 to shareholders of record at the close of business on May 14, 2019.

DUBLIN, May 3, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, will present new data for its investigational implant, Bimatoprost SR, and a late-breaking analysis on its subconjunctival gelatin implant, XEN Gel Stent, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held in San Diego, California from May 3^rd – 7^th. During a podium session on Sunday, May 5^th, Allergan will present an analysis exploring the treatment duration of Bimatoprost SR and a separate presentation on the biodegradation data from a Phase 1/2 study. These presentations follow data that was presented at the most recent Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

DUBLIN, May 2, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that the company will share 29 presentations at the 71^st Annual American Academy of Neurology (AAN) Meeting, including 10 oral podium presentations and 14 poster presentations highlighting the company's science and innovation in migraine. Under the company's migraine franchise, Allergan MIND™ (Migraine: Innovation, Navigation, and Discovery) these 24 presentations represent the largest volume of migraine posters and oral podium presentations at this year's meeting. Additional presentations will highlight data from ongoing studies in adult spasticity (upper and lower limb) and Alzheimer's disease.

DUBLIN, May 1, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the voting results, representing 85.9 percent of shares eligible to be voted, from its Annual General Meeting of Shareholders held on May 1, 2019 in Dublin, Ireland. Shareholders elected all of the 11 nominees as members of the Board of Directors, approved an advisory resolution on executive compensation, ratified the appointment of Allergan's independent auditor for fiscal year 2019, approved proposals related to the authority of the Directors to issue shares under certain specified conditions, and rejected a shareholder proposal calling for an immediate separation of the Chairman and CEO role by majority of votes cast.

DUBLIN, April 25, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in eye care, will present new data at the Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO) to be held in Vancouver, British Columbia from April 28^th - May 2^nd. Data will include three paper presentations on the company's ophthalmology pipeline including new findings evaluating Abicipar in patients with neovascular age-related macular degeneration (nAMD) and Brimonidine Drug Delivery System (DDS) in patients with geographic atrophy secondary to age-related macular degeneration (AMD). Additional company-sponsored data for the investigational Bimatoprost Sustained Release (SR), will also be presented including data analysis from a Phase 1/2, 24-month, prospective, multicenter, dose-ranging study of 75 open-angle glaucoma patients, which evaluated whether continuous drug release with Bimatoprost SR reduces visual field progression rates compared with topical dosing over 24 months.

CINCINNATI, April 15, 2019 /PRNewswire/ -- A new study by the University of Cincinnati Economics Center finds that the Ohio operations of biopharmaceutical company Allergan have a significant impact on the state's economy and communities. The study finds that the annual economic impact of Allergan's manufacturing and packaging facility in Cincinnati includes total output of $46.3 million and total earnings of $28.8 million. Allergan's economic impact is primarily a result of its daily operations and capital investments in Cincinnati, as well as its strong influence on employment in the community. The manufacturing facility, which employs nearly 200 highly skilled workers, supports 686 total jobs directly and indirectly through local investment and daily operations, according to the study. Additionally, Allergan's capital expenditures and operations in Cincinnati generate significant local and state tax revenues with a total fiscal impact of more than $1.3 million in 2017.

DUBLIN, April 15, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that both leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended that the Company's shareholders vote FOR all of the Company's proposals and AGAINST the dissident shareholder proposal ("Proposal No. 6") calling for the immediate separation of Chair and CEO roles at the Company's 2019 Annual Meeting of Stockholders, to be held on May 1, 2019.